News

Biosenta has granted an aggregate of 1,017,000 stock options.

Biosenta announces that it has granted to certain directors, officers, employees and consultants of the Company 350,000 stock options.

Biosenta will enter into a series of prime plus 5% unsecured promissory notes in consideration for cash investments in the amount of $85,000

Today, Biosenta realized its first purchase order and payment from the supply and purchase agreement with SANITIZATION 360.

On December 21, 2020 Biosenta’s U.S. licensing partner Kleen Bee Labs, LLC has secured licensing rights in Ralphs and Food 4 Less retailers.

Biosenta confirms that the management is unaware of any material change that would account for the recent increase in market activity.

Biosenta’s stock closed at 0.75 CAD +0.37 (97.37%). This is in step with Biosenta’s strategic business plan grow the company.

This partnership enables the University team to research nanoparticles for use as antimicrobial filler in commercial construction materials.

A strategic licensing partnership with Kleen Bee Labs was finalized today. This license will give the rights for distribution of DualXtiv.

Biosenta is launching a dual-action, broad-spectrum anti-microbial disinfectant to combat COVID-19 in North America.